

THIS REPORT CONTAINS ASSESSMENTS OF COMMODITY AND TRADE ISSUES MADE BY USDA STAFF AND NOT NECESSARILY STATEMENTS OF OFFICIAL U.S. GOVERNMENT POLICY

Required Report - public distribution

Date: 10/4/2018

GAIN Report Number: GM18038

Germany

Agricultural Biotechnology Annual

2018

Approved By:

Emily Scott

Prepared By:

Leif Erik Rehder

Report Highlights:

Public rejection of genetically engineered (GE) plants in Germany is widespread; there is no commercial GE crop production and practically no foods labeled as Genetically Modified Organisms ("GMO") on the market. Despite this, Germany is home to world-class companies that develop and supply GE seeds globally. The decision of the Court of Justice of the European Union (CJEU) on the regulation of genome editing puts the future of the domestic plant breeding sector in jeopardy. Germany's livestock industry is a major consumer of imported GE soybeans for use as animal feed.

CHAPTER 1: PLANT BIOTECHNOLOGY

PART A: Production and Trade

PART B: Policy PART C: Marketing

CHAPTER 2: ANIMAL BIOTECHNOLOGY

PART D: Production and Trade

PART E: Policy
PART F: Marketing

Executive Summary:

Germany is the most populous and economically powerful country in the European Union (EU). Germany is influential in agricultural policy, both within the EU and globally. Germans are generally open to new technology and willing to innovate, but agricultural biotechnology occupies a unique political space. German society is conflicted regarding agricultural biotechnology and this is reflected in mixed government policies and messaging. Public rejection of GE crops is widespread. Polling shows German public opposition to GE foods runs steadily in the 80 percent range with a presumed high degree of familiarity with the issue. For nearly a generation, German environmental and consumer activists have protested against the use of biotechnology in agriculture – both in Germany and globally. Biotech test plots, which are used both as a research tool and are a required part of the EU regulatory approval process, were destroyed by vandals so often that test plots are no longer attempted in Germany today.

In the current environment there is very little prospect of developing a German market for GE crops or foods, other than the existing feed market for soybeans. Political, business, regulatory, and social barriers raise questions about the long-term competitiveness of German agricultural biotechnology sector. The CJEU decision to regulate products of innovative biotechnology as GE came as a surprise too many and it has sparked a debate about the future of plant breeding in Germany and Europe. There are still around 130 companies engaged in the breeding and marketing of agricultural and horticultural crops in Germany and there are world-class, international seed companies such as Bayer, BASF, and KWS among them. The international companies are major suppliers of both GE and conventionally-bred seeds to markets outside of Europe. However, these major German agricultural companies have since moved research and development operations to the United States; Bayer did so in 2004 and completed the acquisition of Monsanto in June 2018. BASF followed Bayer in 2012 and KWS opened its new U.S. biotech research center in 2015. This is a reaction to negative attitudes toward biotech crops in Europe as well as non-existent consumer markets. Germany, nonetheless, remains a major consumer of GE products since it imports more than six million metric tons of soybeans and soy meal for animal feed annually. In 2018, the U.S. become the top exporter of soybeans to Germany.

CHAPTER 1: PLANT BIOTECHNOLOGY

PART A: PRODUCTION AND TRADE:

- a. PRODUCT DEVELOPMENT: German seed companies such as Bayer Crop Science, BASF, and KWS develop GE plants or crops. However, they have moved their production sites outside of Europe to the United States. In the biomedical industry, more than twenty biopharmaceuticals including genetically engineered enzymes, antibodies, and clotting factors are produced in Germany. These products are regulated under German pharmaceutical laws.
- b. COMMERCIAL PRODUCTION: There is no commercial production of GE crops in Germany. In addition, GE seeds are not produced in Germany for sale abroad. However, German seed companies including Bayer CropScience, BASF, and KWS supply biotech seeds to farmers worldwide from production in the United States Bayer and BASF moved research to North-Carolina while KWS invested in Missouri. With the acquisition of Monsanto in June 2018, Bayer is now also engaged in Missouri.
- c. EXPORTS: There is no commercial production of GE crops in Germany, and Germany does not export GE crops to the United States or other countries.
- d. IMPORTS: Germany is a major livestock producer and is dependent upon imported soy as a feed protein source. Germany imported roughly 5.7 million metric tons (MMT) of soybeans and soybean meal in 2017, nearly all of it produced from GE varieties. Soybean imports totaled 3.0 million metric tons in 2017 with over 51 percent coming directly from the United States. Germany imported 2.7 million metric tons of soybean meal in 2017. For soybean meal, the U.S. just had a tiny market share. The traditional suppliers for soybeans and soybean meal are Argentina, Brazil, and the United States. Soybeans are the largest U.S. agricultural export to Germany. In 2018, the US is expected to expand its market leadership to being the top exporter of soybeans to Germany.
- e. FOOD AID: Germany is not a food aid recipient. The Federal Ministry for Economic Cooperation and Development coordinates a worldwide food aid program under the umbrella of the International Food Aid Convention. Germany also supports the assistance provided by the European Union and the United Nations World Food Programme (WFP).
- f. TRADE BARRIERS: EU policies and legislation lead to biotechnology-related trade barriers that negatively affect U.S. exports.
 - Asynchronous Approvals: New GE crops are entering the global market place at an increasingly rapid rate. The EU regulatory procedures for approving biotech plants take significantly longer than those in supplier countries. This has led to a widening gap between GE products deregulated and grown in the United States and other biotechnology growing countries and those approved in the EU, resulting in the partial or complete disruption of trade in affected commodities and processed products.
 - Low Level Presence: The effect of asynchronous approvals is reinforced by the EU's policy for low level or adventitious presence of events. Commodity trading companies see the risk to their operations increase when trading with countries where GE products are grown, yet

are not-yet approved in the EU.

- Zero tolerance in seeds: Seed trade is affected by the zero tolerance of adventitious presence. The fact that the EU-28 only allows cultivation of MON810, serves as a trade barrier for U.S. seed exports containing or with adventitious presence of other GE events.

PART B: POLICY

a. REGULATORY FRAMEWORK: Within the EU, GE crops and their products are authorized on a case-by-case basis for the uses defined by the applicant. Member States carry out initial risk assessments for the cultivation of GE crops and for the food and feed imports. After weighing the available information, at the EU level, Member States take a majority vote to approve or deny the authorization for imports or to cultivate the GE variety throughout the EU. (EU-28 Biotechnology Annual 2017 has much more detail on the EU regulatory process.) The Federal Office of Consumer Protection and Food Safety (known by its German abbreviation BVL) is the German authority responsible for regulating agricultural GE products. The BVL is an autonomous part of the Federal Ministry of Food and Agriculture (BMEL).

The BVL receives a notification of a GE approval request, passes the notification dossier to the European Food Safety Authority (EFSA), checks the completeness and quality of the data supplied in the dossier, evaluates the risk potential, and issues its own statement to the EFSA. BVL also evaluates the safety of biotech crops that are used in contained systems (i.e., for research or industrial production), and issues environmental release permits and conducts environmental monitoring. The BVL does this under the authority of Germany's Genetic Engineering Act, which implements EU guidelines as national legislation. While primary responsibility for GE policy in Germany rests with BMEL, the Ministries of Economics, Health, Research, and Environment are also involved in the opinion and decision-making process and need to approve Germany's voting decision in EU committees and councils.

As the largest EU Member State, Germany plays a significant role in the regulatory acceptance of GE crops in Europe. This includes voting at the EU level on approvals, transferring and incorporating EU laws into German legislation, establishing liability for GE 'contamination,' and enforcement. Germany also exerts its influence in the politics of biotechnology when it abstains from voting because a quorum of countries is necessary for legislation to pass. This abstention has become usual business in recent years due to disagreements between government ministries.

An EU directive that allows Member States to ban the cultivation of GE crops in their territories for non-scientific reasons was adopted in March 2015. There has been disagreement within government as to whether the ban might cover the entire country or be decided individually by each of the German states (laender). The coalition agreement of the new German government, published in spring 2018, states that the ban on the cultivation of genetically engineered plants (opt-out) will be regulated nationwide. The legislation has not yet come into force. The legislation only affects cultivation and not U.S. exports to Germany.

- b. APPROVALS: The German voting patterns on approvals at the EU level in some ways sharply contrasts with its local regulation of GE crops. Germany abstained from almost every vote since May 2012.
- c. STACKED OR PYRAMIDED EVENT APPROVALS: Stacked events are subject to risk assessment on an EU-level. The approval process is the same as for single events. Risk assessment of stacked events follows the principles provided in EFSA's Guidance Document, which stipulates that where all single events have been assessed, the risk assessment of stacked events should focus mainly on issues related to a) stability, b) expression of the events, and c) potential interactions between the events.
- d. FIELD TESTING: Basic plant science research is very strong in German universities, where transgenic plants are routinely created to test gene function and answer other biological questions. However, scientists face a strong incentive to work outside of Germany if they wish to develop new crop varieties using biotechnology. In the past, German companies and universities conducted small field trials of biotech plants, but the number has decreased dramatically over the last few years. In 2007, experimental releases totaled nearly 70 hectares; today there are no field trials.

German law requires the researchers publically publish the exact location of a test plot on the internet. This made it easy for activist to vandalize the plots (here is a link to the mapping system). Vandalism is a significant barrier to conducting field trials in Germany.

e. INNOVATIVE BIOTECHNOLOGIES: The election in September 2017 resulted in a government coalition of the Christian Democratic Union (CDU), the Christian Social Union of Bavaria (CSU), and the Social Democrats (SPD), as was its immediate predecessor. Their coalition agreement outlines objectives for the next three and a half years. For genetic engineering and innovative biotechnologies, the coalition agreement refers to the, "ECJ decision whether NBT's, such as CRISPR/Cas, are to be legally classified as a genetic modification. Then, the coalition will establish rules on the European and/or national level that ensure the application of the precautionary principle and freedom of choice."

The CJEU decided on July 25, 2018 that genome editing falls under the legislation for GE products. Since then, the decision and its effects have been discussed in media and there is disagreement within the German government between SPD and CDU/CSU. Julia Kloeckner, CDU and Federal Minister for Food and Agriculture, publically commented the CJEU decision,

"We must have a debate that is science-based... I think it is factually wrong to lump classic green genetic engineering together with CrisprCas. It will be seen whether there will be legislative changes. The debate is not over yet. We must be careful not to put an end to a new technology from luxury positions of abundance in Europe. The new technology could become the solution to agricultural problems. It could be used, for example, to breed drought-resistant plants." - Minister Kloeckner

In principle, CDU/CSU acknowledge the great potential of innovative biotechnologies, such as CRISPR/Cas9, for a more efficient, faster, and more cost-efficient plant breeding. Thus,

CDU/CSU wants to develop a "biotechnology agenda" to create jobs and advocated in favor of a process and product-related assessment in the context of individual case studies before the CJEU ruling.

The coalition partner SPD is opposed towards the use of agricultural biotechnology and advocates for strict regulation of innovative biotechnologies. Matthias Miersch, Deputy chairman of the SPD parliamentarians and coalition partner of Minister Kloeckner, answered publically to Kloeckner's statement towards legislative changes, "new biotech processes, such as CrisprCas and the products produced with them, are subject to genetic engineering law. The ruling of the European Court of Justice should also be recognized by the Federal Minister of Agriculture." Svenja Schulze, SPD and Federal Minister for Environment, Nature Conservation and Nuclear Safety stated that, "the ECJ ruling is good news for environment and consumer protection. The ruling demonstrates clear commitment to the precautionary principle in Europe and it gives the necessary legal certainty and transparency for consumers, research and industry."

- f. COEXISTENCE: Germany's policy of "coexistence" between GE and conventionally-grown and organic crops is biased against the use of GE crops. Since there is no GE cultivation in Germany, coexistence regulations are currently theoretical. But in the past, German federal and local governments put into place an assortment of planting bans, segregation distances, and other requirements. For instance, Germany requires a minimum distance of 150 meters a U.S. football field-and-a-half between biotech and conventional fields, and a minimum distance of 300 meters between biotech and organic cornfields.
- g. LABELING: Germany applies EU regulations for labeling GE foods (Regulations EC 1829/2003 and 1830/2003). No foods labeled as containing "GMO" are sold in Germany. Under EU rules, foods require a "GMO" label only if GE crops are used as an ingredient. There is no required labeling for meat or dairy products coming from animals fed with GE feeds. In May 2008, the German government created a voluntary "Ohne Gentechnik" (GE-free) labeling program. In August 2009, the Ministry for Food, Agriculture and Consumer Protection introduced a national label to help consumers better identify products and to standardize the information consumers receive.
- h. MONITORING AND TESTING: Germany has a decentralized system for testing and controlling the illegal entry of GE products into Germany. The German laender each have the authority with the competence to ensure that no unauthorized biotech product enters the German retail market. The laender each have their own monitoring and sampling plans. Since the experts know the kind of products that potentially contain GE events, they specifically sample for these products. Sampling is primarily done at the wholesale and the processing level.
 - Germany fully enforces EU rules relating to GE crops. The Rapid Alert System for Food and Feed (RASFF) is used to report food safety issues to consumers, the trade, and other Member-States. In the case of biotech crops, Germany's 16 laender test for unauthorized GE products and report violations via the RASFF.
- i. LOW-LEVEL PRESENCE (LLP) POLICY: Germany does not have its own LLP policy. Rather, it fully implements EU Regulation 619/2011, which details official sampling methods

- and analysis This "technical solution" threshold is 0.1 percent, which defines zero (as in zero tolerance). The EU "technical solution" is not an actual LLP policy.
- j. ADDITIONAL REGULATORY REQUIREMENTS: German farmers producing GE crops must register their fields with the governmental body BVL three months before planting.
- k. INTELLECTUAL PROPERTY RIGHTS: German intellectual property law mainly consists of the Copyright Act (UrhG), Patent Act (PatG), Trademark Act (MarkenG), Utility Model Act (GebrMG) and Design Rights Act (GeschMG), flanked by some provisions of the Civil Code (BGB) and the Act Against Unfair Competition (UWG). All of these bodies of law have histories dating back to before German membership in the EU but have since been revised and amended several times to implement European Directives and Guidelines or treaties. However, in Germany, the Plant Variety Protection Act protects the intellectual property of new varieties of plants. A breeder can apply for plant variety protection for a new variety at the Federal Office of Plant Varieties (BSA). In Germany, plant variety protection is an intellectual property right separate from a patent.
- 1. CARTAGENA PROTOCOL RATIFICATION: Germany signed the Cartagena Protocol on Biosafety on May 24, 2000. It was ratified in November 2003 and entered into force on February 2004.
- m. INTERNATIONAL TREATIES/FORUMS: Germany is a member of several international organizations dealing with plant protection and plant health like the European and Mediterranean Plant Protection Organization, the Organization for Economic Co-operation and Development, The Food and Agriculture Organization of the United Nations, and Codex. The Federal Republic of Germany is the host country for a subsidiary body of the Codex Alimentarius Commission, the Codex Committee on Nutrition and Foods for Special Dietary Uses. Germany does not actively participate in discussion related to GE plants.

n. RELATED ISSUES:

For the past several years, the German Green Party, supported by a range of non-governmental organizations (NGOs), has introduced policy proposals to end the importation of GE soybeans into Germany. Under several proposals, soy imports would be replaced by domestically produced pulses and other protein crops. However, a full replacement of imported protein feeds does not appear to be a realistic option in the near term.

PART C: MARKETING

a. PUBLIC/PRIVATE OPINIONS: Years of controversy have produced a large number of polling studies on German and European attitudes toward GE crops. A very comprehensive study comes from the European Commission/Eurostat and is titled Europeans and Biotechnology – Winds of Change (2010). Four findings from this study relative to the marketing of U.S. agricultural products include: 1) opposition to GE foods is high and steady over time; 2) the level of support for GE foods is declining; 3) familiarity with the technology or science does not improve attitudes; and 4) educating consumers does not increase GE crop acceptance (implying that messaging is more important than facts).

b. MARKET ACCEPTANCE: For nearly a generation, German consumers have been exposed to consistent messaging from NGOs that biotech crops are dangerous, a product of exploitive capitalism and even immoral. As a result, the use of biotech crops in foods is a highly contentious and politicized issue. Since biotech crops were first introduced in the mid-1990s, attempts to educate consumers and opponents about the benefits of biotech crops and about the science in general have proven ineffective. German public opposition to GE foods has run steadily in the 80 percent range.

According to the Federation of Food Law and Food Science, an estimated 60-80 percent of all food in German supermarkets has come in contact with biotech products in some way. The Union of German Academies of Science has concluded that objections to biotech in agriculture lack any scientific basis, and agricultural biotech tends to find stronger support among consumers with postgraduate degrees.

Although the EU has approved numerous biotech plants that would theoretically be legal to sell in Germany, practically no labeled biotech foods are on the market. One contributing factor is the concentration of the food retail sector and its vulnerability to narrowly focused consumer activists. The German retail food sector is dominated by five large retailers, which have more than 90 percent of the market. Germany also has the highest market share of the world's discount retail food stores. Within this low-margin and concentrated industry, anti-biotech NGOs would likely target any retailer offering GE-labeled products. This presents an unacceptable brand risk that hinders the introduction of GE-labeled foods.

CHAPTER 2: ANIMAL BIOTECHNOLOGY

PART D: PRODUCTION AND TRADE

- a. PRODUCT DEVELOPMENT: In Germany, research into GE animal biotechnology and cloning is mainly at the Friedrich Loeffler Institute (FLI) in its Animal Genetics unit. This is conducted in "closed system" laboratories. There is no production of cloned animals in Germany.
- b. COMMERCIAL PRODUCTION: There is no commercial production of GE animals and cloning in Germany.
- c. EXPORTS: As there is no commercial production, there are no exports.
- d. BIOTECHNOLOGY IMPORTS: There are no known imports of GE animals or cloned animals for agricultural purposes into Germany. Germany has imported unknown numbers of genetics and offspring from clones as part of normal herd improvement programs, particularly in the dairy sector.
- e. TRADE BARRIERS: Most GE-related trade barriers in Germany have their origins in EU regulation, especially the slow EU approval process for GE varieties commonly planted outside of Europe.

PART E: POLICY

- a. REGULATORY FRAMEWORK: Germany implements the EU Regulation on animal biotechnology. Please see EFSA GE animal website: https://www.efsa.europa.eu/en/topics/topic/gmanimals
- b. APPROVALS: There is no GE animal approved or registered in Germany for use.
- c. INNOVATIVE BIOTECHNOLOGIES: There are no known current or pending German regulations of these technologies in animals. The EU has guidance and EFSA published guidance for food and feed derived from GE animals and also a guidance on environmental risk assessment. Please see (https://www.efsa.europa.eu/en/efsajournal/pub/2501) (https://www.efsa.europa.eu/en/efsajournal/pub/3200)
- d. LABELING AND TRACEABILITY: No policy.
- e. INTELLECTUAL PROPERTY RIGHTS (IPR): German intellectual property law mainly consists of the Copyright Act (UrhG), Patent Act (PatG), Trademark Act (MarkenG), Utility Model Act (GebrMG) and Design Rights Act (GeschMG), flanked by some provisions of the Civil Code (BGB) and the Act Against Unfair Competition (UWG). All of these bodies of law have histories dating back to before German membership in the European Union (EU) but have since been revised and amended several times to implement European Directives and Guidelines or treaties.
- f. INTERNATIONAL TREATIES/FORUMS: As a member of the EU, Germany is a member of Codex Alimentarius. Germany is also a member of the World Organization for Animal Health (OIE). Germany does not actively participate in discussion related to GE plants or cloning.
- g. RELATED ISSUES: The election in September 2017 resulted in a government coalition of the Christian Democratic Union (CDU), the Christian Social Union of Bavaria (CSU), and the Social Democrats (SPD), as was its immediate predecessor. Their coalition agreement outlines objectives for the next three and a half years and clearly rejects the use of cloning for food production.

The German Parliament unanimously voted against the cloning of animals on May 8, 2015. The motion includes cloning of animals for food production and labeling of cloned animals, their offspring, and products derived therefrom. With its motion, the German parliament challenges an EU proposal which prohibits cloning in food production but not the import of offspring of clones and their meat or milk.

PART F: MARKETING

a. PUBLIC/PRIVATE OPINIONS: Animal biotechnology is currently not high on the political agenda, and there is currently no high-profile lobbying for or against the use of livestock cloning

or GE animals. However, public views on cloning are widely believed to be similar to those held for GE crops. Past EU-level debates on the regulation of cloning have not received positive media coverage. There has been limited media coverage of cloning in the context of endangered or extinct species. That coverage was fairly balanced.

b. MARKET ACCEPTANCE/STUDIES: There is little awareness of GE animals or cloning among the German public. There are no known studies specific to Germany on the marketing GE animals or clones.